Victory Capital Management Inc. Reduces Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Victory Capital Management Inc. reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 13.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,893,193 shares of the medical equipment provider’s stock after selling 764,824 shares during the quarter. Victory Capital Management Inc. owned approximately 2.11% of Hologic worth $398,600,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of HOLX. Price T Rowe Associates Inc. MD grew its stake in Hologic by 77.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after purchasing an additional 2,753,016 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in Hologic by 21.6% during the second quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock worth $188,243,000 after purchasing an additional 450,190 shares during the last quarter. Black Creek Investment Management Inc. lifted its position in Hologic by 60.9% during the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after acquiring an additional 885,524 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Hologic by 5.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock valued at $172,780,000 after buying an additional 124,739 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Hologic by 4.0% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock valued at $168,666,000 after acquiring an additional 87,176 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

Shares of Hologic stock traded down $0.35 during trading on Tuesday, reaching $79.04. The company’s stock had a trading volume of 203,236 shares, compared to its average volume of 1,585,202. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67. The stock has a 50-day moving average price of $80.93 and a two-hundred day moving average price of $78.19. The company has a current ratio of 3.69, a quick ratio of 3.32 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $18.36 billion, a P/E ratio of 23.84, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.89 earnings per share. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on HOLX shares. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price target on shares of Hologic in a research report on Tuesday, October 15th. Leerink Partners dropped their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Royal Bank of Canada boosted their price target on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. UBS Group raised their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Raymond James increased their target price on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and an average price target of $89.25.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.